Lila Bio lands $3.65M grant to fight pulmonary hypertension with AI-designed proteins

Seattle-based biotech startup Lila Bio received a $3.65 million grant from the National Institutes of Health (NIH) to develop a potential new treatment for pulmonary hypertension, a serious condition that causes high blood pressure in the arteries connecting the heart and lungs. The company is using AI to design a treatment that could address the underlying disease rather than only manage its symptoms.

Founded in 2023 by former University of Washington researchers Jake Kraft and Anindya Roy, Lila Bio grew out of Nobel Prize winner David Baker’s lab at UW’s Institute for Protein Design. The NIH funding will support early testing of a potential treatment that could be administered through injections just a few times a year. The company previously raised $10 million in seed funding and announced a collaboration with Eli Lilly to develop cancer treatments.

Lila Bio’s success in securing both private investment and federal funding highlights the opportunities available for biotech startups in Washington. From university research to early-stage funding, the state offers an environment where entrepreneurs can access the support needed to grow their companies and advance promising treatments.

READ THE STORY at GeekWire»